Clinical trials coverage from Pharma Journal: trial design, regulatory milestones, patient recruitment and phase readouts across the UK and global pipeline. The studies shaping tomorrow's medicines, from first-in-human work to pivotal results and the approvals that follow.
The primary endpoint data from the EVOKE and EVOKE Plus trials, presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in late 2024 and subsequently reported in Nature Medicine (2025), show that semaglutide (Novo Nordisk; Ozempic at 1mg subcutaneous weekly)…
By Tom Okafor, Clinical Trials Correspondent
A bespoke mRNA vaccine built from a patient’s own tumour, given with Keytruda, kept high-risk melanoma from returning in a phase 3 trial. The proof of principle now shifts the hard problem to manufacturing and regulation.
By Tom Okafor, Clinical Trials Correspondent
The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, signed into law in April 2025 and entering into force on 28 April 2026, represent the most substantial revision to the UK clinical trial regulatory framework since the original 2004 Regulations…
By Dr. Eleanor Vance, Regulatory Affairs Editor
DTP3 multiple myeloma development targets a cancer-restricted NF-kB survival switch. Could this first-in-class peptide open a new lane for relapsed and refractory patients?
By Tom Okafor, Clinical Trials Correspondent
The UK is advancing in vivo CRISPR gene editing beyond ex vivo models. Explore regulatory signals, lipid nanoparticle delivery, and NHS reimbursement challenges.
By Dr. Eleanor Vance, Regulatory Affairs Editor
Microbiome on chip systems could revolutionise drug discovery by providing human-relevant gut testing, potentially reducing the 90% clinical trial failure rate.
By Tom Okafor, Clinical Trials Correspondent
The UK clinical trial regulation package, taking effect on 28 April 2026, is designed to deliver faster, more predictable approvals while preserving participant protections. Its headline operational c
By Tom Okafor, Clinical Trials Correspondent
AI drug discovery shifts from promise to operational impact as pharma adopts risk-on posture amid tightening patent cliff timeline in 2026.
By Tom Okafor, Clinical Trials Correspondent
The United Kingdom enters 2026 as one of the most active environments in the world for high-paying clinical trials, particularly early phase studies involving healthy volunteers. Regulatory reforms, f
By Tom Okafor, Clinical Trials Correspondent
Clinical research is the cornerstone of modern medicine, driving the development of new drugs, therapies, and medical technologies. Over the past decade, rapid advancements in artificial intelligence
By Tom Okafor, Clinical Trials Correspondent
The landscape of IVF advancements in 2025 is undergoing a remarkable transformation, driven by cutting-edge research and technological breakthroughs. Scientists and fertility experts are developing ne
By Tom Okafor, Clinical Trials Correspondent
The scientific world has witnessed a groundbreaking achievement with the release of the latest data from the Human Cell Atlas project. This international initiative has been years in the making, assem
By Tom Okafor, Clinical Trials Correspondent
The fight against melanoma, the deadliest form of skin cancer, has taken a revolutionary step forward with the introduction of a personalised vaccine now in clinical trials in Britain. This groundbrea
By Tom Okafor, Clinical Trials Correspondent
Subscribe to our weekly pharmaceutical intelligence digest
We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy